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Abstract
Plasma-cell neoplasms are classically categorized into four groups as: multiple myeloma (MM), plasma-cell leukemias, 
solitary plasmacytomas (SP) of the bone (SPB), and extramedullary plasmacytomas (EMP). These tumors may be 
described as localized or diffuse in presentation. Localized plasma-cell neoplasms are rare, and include SP of the skeletal 
system, accounting for 2-5% of all plasma-cell neoplasms, and EMP of soft tissue, accounting for approximately 3% of 
all such neoplasms. SP is defined as a solitary mass of neoplastic plasma cells either in the bone marrow or in various soft 
tissue sites. There appears to be a continuum in which SP often progresses to MM. The main treatment modality for SP 
is radiation therapy (RT). However, there are no conclusive data in the literature on the optimal RT dose for SP. This review 
describes the interrelationship of plasma-cell neoplasms, and attempts to determine the minimal RT dose required to 
obtain local control. (Turk J Hematol 2010; 27: 57-61)
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Özet
Plazma hücre malignitesi klasik olarak dört gruptur: multiple myelom (MM), plazma hücre lösemisi, kemik yerleşimli soliter 
plazmasitom (SPB) ve ekstrameduller yerleşimli plazmasitom (EMP). Lokalize plazma hücre malignitesini iskelet sistemi 
yerleşimli SP ve EMP oluşturur. Plazmasitoma birçok farklı şekilde tanımlanabilir. Çoğunlukla kemik iliğinde veya yumuşak 
dokuda plazma hücrelerinden oluşan bir kitle şeklinde görülür. Henüz, soliter plazmositomların MM’a dönüşümü arasinda-
ki ilişki tam olarak tanımlanmamıştır. Soliter plazmositomlar, hem SPB hem de EMP için ana tedavi radyoterapidir. Ancak, 
SP için uygun tedavi dozu için ortak bir data yoktur. Lokal kontrol için optimal doz hastalığın yerine ve boyutuna bağlı 
olarak 30 ve 50 Gy arasında değişmektedir. Bu derlemede lokal kontrol için minimal RT dozu tanımlanmaya çalışılmıştır. 
(Turk J Hematol 2010; 27: 57-61)
Anahtar kelimeler: Soliter plazmasitom, radyoterapi, multipl miyelom, tedavi yaklaşımı
Geliş tarihi: 17 Eylül 2009    Kabul tarihi: 3 Mart 2010Introduction
Plasma-cell neoplasms account for approximately 1-2% of 
human malignancies, and occur at a rate of 3.5/100,000 per 
year. Plasmacytoma, a clonal neoplastic disorder of bone mar-
row originating from plasma cells, the last maturation stage of 
B lymphocytes, may appear as four different diseases: multiple 
myeloma (MM, systemic disease), plasma-cell leukemias, extra-
medullary plasmacytoma (EMP), and solitary plasmacytoma 
(SP) of bone (SPB). This review article assesses the manage-
ment of SPs, as the treatment of MM is mainly with systemic 
chemotherapy, and the role of local radiotherapy (RT) is restrict-
ed for palliation of symptoms. A diagnosis of SP is made when 
all the following criteria are satisfied [1]: a histologically con-
firmed single lesion with negative skeletal imaging outside the 
primary site, normal bone marrow biopsy (less than 10% mono-
clonal plasma cells), and no myeloma-related organ dysfunc-
tion. Men are affected more than women (male-to-female ratio 
2:1) [2]. The median age at the diagnosis of SP ranges between 
55 and 65 years, on average about 10 years younger than 
patients with MM. EMPs are less common than SPBs [2-4]. 
Laboratory signs of SP are usually related to the immunoglobu-
lin production, if the secretory component is present. 
Solitary plasmacytoma most commonly presents in bone 
(80%). SPBs are most often found in the axial skeleton, usu-
ally the vertebrae and skull [2]. Patients usually present with 
bone pain, sometimes associated with neurologic compromise 
and/or pathologic fracture. Less commonly, SP presents in an 
EMP site (20%), usually found in the head and neck, and most 
often in the nasal cavity and nasopharynx [2,3,5,6]. The histo-
logic diagnosis of EMP can be difficult, and the main differential 
diagnosis is extranodal marginal zone lymphoma [5,7].
Diagnostic Work-Up
Diagnostic work-up at the presentation includes history, 
physical examination, complete blood count, bone marrow 
biopsy, serum protein electrophoresis, evaluation of the urine 
for myeloma protein, and skeletal survey. The incidence of a 
monoclonal gammopathy (M-protein) is present in 30-75% of 
cases (especially for bone presentation, usually minimally ele-
vated [IgG <5 g/L, IgA <20 g/L], and urine monoclonal kappa 
or lambda <1.0 g/24 h) [8-9]. Tsang et al. [4] observed the fol-
lowing myeloma protein levels in the blood of 46 patients with 
SP: normal 59%, minimally elevated 28% and elevated 13%.
Skeletal survey is preferred over bone scintigraphy because 
the latter is only 40-60% sensitive for detecting bone lesions 
since the osteoblastic response to bone destruction by myelo-
ma is negligible. Approximately 25-50% of bone trabeculae 
must be destroyed with a bone defect to be visible on a plain 
radiography. Thus, computed tomography (CT) is more sensi-
tive for detecting the extent of bone destruction. Some patients 
with suspected SPB will be upstaged following magnetic reso-
nance imaging (MRI) with the detection of multiple vertebral 
lesions or bone marrow disease, with lesions being darker or 
isointense on T1-weighted images and hyperintense on 
T2-weighted images and enhanced with contrast [10-11] or 
positivity on 18F-fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) [12,13].
Management of Solitary Plasmacytoma
Radiation therapy (RT) is the standard treatment for SP. 
Surgery is considered for bone instability, fracture, or when 
there is rapidly progressive neurologic deterioration such as 
spinal cord compression [1,14]. For patients treated with surgi-
cal excision, RT is still indicated to eradicate microscopic 
residual disease. Surgery alone without RT leads to an unac-
ceptably high local recurrence rate [2]. A review of the recent 
literature for SPB indicated high local control rates with RT (79-
91%) but a modest overall survival of approximately 50% at 10 
years. Özşahin et al. [2] reported local control was better with 
small tumors (<4 cm) in patients treated with RT; however, no 
difference was observed between bone and extramedullary 
SP. This is because of a high progression rate to MM, a finding 
consistently reported by many investigators [2,4,15-18]. Over 
60% of patients with SPB will progress to myeloma, usually 
within two to four years after treatment. Özşahin et al. [2] 
showed that SP seemed to develop MM in two peaks. A first 
peak during the first three years post-treatment is probably due 
to undetected existing MM by an asymptomatic gross disease 
becoming more obvious; a second peak, corresponding to a 
real MM development of previously occult disease, is observed 
after 6-9 years. Therefore, it appears SPB may be an early form 
of MM. Vertebral disease has been reported to be a poor prog-
nostic factor compared to other bony localization [2]. The pres-
ence of low level M-protein pre-radiation is very common, and 
by itself is not associated with a higher risk of progression to 
MM. Patients showing persistent M-protein levels for more 
than one year after RT are prone to progress to MM [16,19].
The addition of adjuvant chemotherapy to RT is, theoreti-
cally, attractive in an attempt to eradicate subclinical disease to 
prevent the disease relapsing as myeloma. Only one random-
ized trial suggested a benefit with adjuvant melphalan and 
prednisone given for three years after RT compared to RT 
alone [20]. However, this was a small study and the concerns 
regarding prolonged use of alkylating agents on the bone mar-
row do not justify its routine use. This study concluded that 
combined radiochemotherapy seemed to increase remission 
and survival duration.
Targeting the mechanisms that control angiogenesis, 
which have an integral role in the pathophysiology of hemato-
logic malignancies, could be an innovative therapeutic 
approach in the treatment of SP. Kumar et al. [19] reported 
high-grade angiogenesis in 64% of tumors in their series of 25 
SPB patients, and found that angiogenesis is highly correlated 
with progression to MM. Therefore, antiangiogenic compounds 
such as thalidomide, vascular-endothelial growth factor or 
proteasome inhibitors may be promising in this disease.
For EMP, complete surgical excision may be curative for 
small lesions. However, most patients with larger lesions or with 
tumor location not amenable to complete excision should receive 
local RT, and postoperative RT is indicated for incompletely 
excised lesions. In contrast to bone localization, EMPs are well 
controlled with local radiation. Of all plasma-cell tumors, EMPs 
have the best prognosis [5]. Evidence of local involvement of 
adjacent bone and/or lymph nodes does not necessarily indicate 
systemic disease, or signify a worse prognosis [21]. Conversion 
to MM is less likely than in patients with SPB with the best result 
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Moreover, a substantial proportion of patients are cured of their 
disease. Although the 10-year survival varies widely in the recent 
literature (range: 50-78%), the two largest series reported 
10-year survival rates of 72% [2] and 78% [21] (Tables 1, 2).
Radiation Therapy
The optimal treatment of most patients with SP is moder-
ate-dose RT. Approximately 40-50 Gy are administered once 
daily at 1.8-2.0 Gy per fraction in a continuous course. For RT 
planning, MRI is extremely useful to delineate the gross tumor 
volume (GTV), both within and beyond the bone. This is impor-
tant for the head and neck areas (e.g., paranasal sinuses), 
where inflammatory changes may be difficult to distinguish 
from tumor on CT scan. The FDG-PET could be used to delin-
eate the tumor and response to treatment; however, the role 
of FDG-PET in defining tumor extent to assist in RT planning 
requires further investigation [12].
Clinical target volume (CTV) should encompass probable 
routes of microscopic spread, recognizing that barriers to the 
extension of local disease will vary according to the anatomical 
location, as will the morbidity of treating adjacent normal tis-
sues. Jyothirmayi et al. [25] reported that, among 30 patients 
with SP treated with RT that encompassed only the tumor with 
a margin, no marginal recurrence was seen. Prophylactic 
regional lymph node coverage is not necessary in SPB, as the 
regional nodal failure rate is low after local RT without inten-
tional coverage of adjacent nodes [4,23,25,26]. For EMP, 
nodal involvement at presentation is observed in only 10-20% 
of the patients, and planning target volume (PTV) does not 
justify covering the regional lymph nodes [2]. Strojan et al. [3], 
in a series of 26 patients, concluded that prophylactic nodal 
radiation is probably unnecessary.
Planning target volume (PTV) should account for setup 
variation from day to day and organ motion issues, typically 
adding 5-10 mm to the CTV depending on the immobilization 
technique employed. Although parallel-opposed fields are 
commonly adequate to encompass disease, CT-based plan-
ning and the use of conformal or intensity-modulated RT 
(IMRT) techniques should be used when needed to treat the 
PTV adjacent to critical structures. This is especially important 
in extramedullary disease involving the head and neck areas 
where avoidance of the eyes, optic nerves, and salivary glands 
is desirable to minimize morbidity.
Solitary plasmacytomas are radiation-sensitive tumors. 
Most studies documented response rates of 85% or more for 
patients treated with 35 Gy or more. Some investigators 
reported better local control following doses of 45 Gy or more 
[6,27], while others have found no indication of improved out-
come with higher doses [2,26]. A dose-response analysis of 81 
patients by Mendenhall et al. [2,25] led to a recommendation 
of a minimum dose of 40 Gy for both bone and extramedullary 
SP. In their study, a total dose of 40 Gy or more gave a local 
failure rate of 6%, compared with a suboptimal 31% for lower 
doses [24]. Therefore, the standard practice is to administer a 
dose of 40-45 Gy or even higher for bulky tumors. However, in 
one of the largest studies (n=258), there was no evidence of 
improved local control with RT doses increasing from 30-50 
Gy, even for the subset of patients with tumors larger than 4 
cm [2]. In fact, there was a worse local control rate for the 
group receiving a total dose of 50 Gy or more, although this 
was not statistically significant [2]. These findings should be 
interpreted carefully because in these retrospective studies, 
dose-response rates are typically confounded by selection 
bias, as high doses are to be prescribed to larger tumors with 
worse prognosis.
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Table 1. Solitary plasmacytoma of bone
Author   n  LC  MMFS  DFS  OS
Tsang RW [4]  32  78% (8 yrs)  36% (8 yrs)  -  -
Knobel D [15]  206  79% (10 yrs)  51% (10 yrs)  46% (10 yrs)  50% (10 yrs)
Wilder RB [16]  60  90% (10 yrs)  38% (10 yrs)  57% (10 yrs)  59% (10 yrs)
Kılçıksız S [17]  57  94% (10 yrs)  Median 4.1 yrs  Median 3.2 yrs  68% (10 yrs)
Bolek TW [18]  27  96%  0% (15 yrs)  -  23% (15 yrs)
Note: Time interval (in parentheses) indicates follow-up point at which the outcome was observed
LC: Local control; DFS: Disease-free survival; MMFS: Multiple myeloma-free survival; OS: Overall survival
Table 2. Extramedullary plasmacytoma 
Author   n  LC  MMFS  DFS  OS
Özşahin M [2]  52  74%  36% (10 yrs)  55% (10 yrs)  72% (10 yrs)
Strojan P [3]  26  87% (10 yrs)  92% (10 yrs)  87% (10 yrs)  61% (10 yrs)
Tsang RW [4]  14  93% (8 yrs)  84% (8 yrs)  -  -
Tournier-Rangeard L [6]  17  88.2% (10 yrs)  63.8% (10 yrs)  53.5% (10 yrs)  63.4% (10 yrs)
Liebross RH [8]  22  95%  56% (5 yrs)  78% (5 yrs)  -
Kılçıksız S [17]  23  95% (10 yrs)  Median 7.4 yrs  Median 7.4 yrs  89% (10 yrs)
Bolek TW [18]  10  100%  67% (15 yrs)  -  80% (15 yrs)
Note: Time interval (in parentheses) indicates follow-up point at which the outcome was observed
LC: Local control; DFS: Disease-free survival; MMFS: Multiple myeloma-free survival; OS: Overall survivalDurable local control is obtained in 85% of small tumors 
(<5 cm) with 35-40 Gy, and there is little evidence that higher 
doses are necessary, regardless of bone or extramedullary 
locations. However, SP of >5 cm have worse local control 
[2,4], and doses of 45-50 Gy are recommended in these larger 
tumors. Despite this, one should be aware that the quality of 
evidence supporting the use of higher RT doses is limited, and 
local recurrences are still infrequently observed even after 
doses exceeding 50 Gy [2,4]. Özşahin et al. [2] recommended 
a minimum dose of 45 Gy should be prescribed even for 
patients who undergo surgery. Conversely, in the event of a 
bulky tumor and no surgery, a dose to the CTV could be even 
higher than 45 Gy, possibly 50 Gy, to improve local control.
Prognostic Factors Affecting the Outcome
Advanced age is clearly associated with poor survival [2]. 
Similarly, higher risk of progression to MM was observed in the 
elderly in some studies [4,19,28] but not confirmed by others 
[2,29-32]. A bony presentation was consistently demonstrated 
to have a higher risk of MM progression with a 10-year rate of 
76%, compared with an extramedullary presentation, in which 
the 10-year MM rate was 36% [2]. Subclinical osteopenia [33] 
or abnormal MRI scan of the spine [10,34,35] reflects presence 
of occult disease, and predicts rapid progression to systemic 
myeloma. A suppression of the normal immunoglobulin class-
es, also known as immunoparesis, correlates with a higher risk 
of progressing to MM [33,36]. M-protein levels are reported to 
be a predictive factor of occult disseminated disease, and 
patients showing persistent M-protein levels for more than one 
year after RT are prone to progress to MM [8,16,37]. Anaplastic 
plasmacytomas (those with a higher histologic grade) [26] and 
tumors with a high level of angiogenesis [9] are associated with 
poorer outcomes.
Tumor size is reported to be an important prognostic factor 
in terms of local control. According to Tsang et al. [4], in tumors 
smaller than 5 cm, a high level of local control was achieved 
with 35 Gy, whereas those 5 cm or larger had a local failure 
rate of 58%. The importance of tumor bulk is also supported 
by others [2,30,31].
Follow-Up
Since there is a significant risk of recurrence of disease as 
MM, repeat measurements of M-protein may detect the onset 
of systemic disease prior to the development of symptoms 
[16]. Complete blood counts should be taken periodically to 
evaluate bone marrow function. The occurrence of new bone 
pain requires further investigations, including imaging as 
appropriate. 
Conclusion
Solitary plasmacytoma is a relatively uncommon malignan-
cy that frequently presents in the vertebrae (SPB) or head and 
neck (EMP). Most patients are treated with moderate-dose RT. 
Some investigators reported better local control following 
doses of 45 Gy or more [6,27], while others have found no 
indication of improved outcome using higher doses [2,26]; a 
subset of patients may require surgical intervention. At the 
present time, adjuvant chemotherapy is not indicated. 
The likelihood of local control after treatment is high. The most 
common pattern of relapse is systemic myeloma progression, 
which is more likely to occur after treatment for SPB compared 
with EMP. Strategies to improve outcome will be related to 
improved management of MM in the subset of patients who 
develop systemic relapse. Future prospective studies should 
focus on the use of adjuvant chemotherapy and/or novel 
therapeutic agents, i.e., proteosome inhibitors.
Conflict of interest
No author of this paper has a conflict of interest, including 
specific financial interests, relationships, and/or affiliations rel-
evant to the subject matter or materials included in this man-
uscript.
References
1.  Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, 
Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, 
Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales 
AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, 
San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, 
Tricot G, Van Ness B. Myeloma management guidelines: a 
consensus report from the Scientific Advisors of the International 
Myeloma Foundation. Hematol J 2003;4:379-98.
2.  Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, 
Oner Dincbas F, Landmann C, Castelain B, Buijsen J, 
Curschmann J, Kadish SP, Kowalczyk A, Anacak Y, Hammer J, 
Nguyen TD, Studer G, Cooper R, Sengöz M, Scandolaro L, 
Zouhair A. Outcomes and patterns of failure in solitary 
plasmacytoma: A multicenter Rare Cancer Network study of 
258 patients. Int J Radiat Oncol Biol Phys 2006;64:210-7. 
3.  Strojan P, Soba E, Lamovec J, Munda A. Extramedullary 
plasmacytoma: clinical and histopathologic study. Int J Radiat 
Oncol Biol Phys 2002;53:692-701. 
4.  Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, 
Hodgson DC, Stewart AK. Solitary plasmacytoma treated with 
radiotherapy: impact of tumor size on outcome. Int J Radiat 
Oncol Biol Phys 2001;50:113-20.
5.  Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, 
Schratzenstaller B, Arnold W. Extramedullary plasmacytoma: 
tumor occurrence and therapeutic concepts. Cancer 
1999;85:2305-14. 
6.  Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, Mege A, 
Dolivet G, Toussaint B, Charra-Brunaud C, Hofstetter S, 
Marchal C, Peifert D. Radiotherapy for solitary extramedullary 
plasmacytoma in the head-and-neck region: A dose greater 
than 45 Gy to the target volume improves the local control. Int 
J Radiat Oncol Biol Phys 2006;64:1013-7.
7.  Hussong JW, Perkins SL, Schnitzer B, Hargreaves H, Frizzera G. 
Extramedullary plasmacytoma: a form of marginal zone cell 
lymphoma? Am J Clin Pathol 1999;111:111-6. 
8.  Van de Berg BC, Lecouvet FE, Michaux L, Labaisse M, Malghem 
J, Jamart J, Maldague BE, Ferrant A, Michaux JL. Stage I multiple 
myeloma: value of MR imaging of the bone marrow in the 
determination of prognosis. Radiology 1996;201:243-6. 
9.  Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Wellik L, 
Witzig TE, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV. 
Prognostic value of angiogenesis in solitary bone plasmacytoma. 
Blood 2003;101:1715-7.
Koçak et al.
Solitary plasmacytoma Turk J Hematol 2010; 27: 57-61 6010.  Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. 
Solitary bone plasmacytoma: outcome and prognostic factors 
following radiotherapy. Int J Radiat Oncol Biol Phys 
1998;41:1063-7.mination of prognosis. Radiology 
1996;201:243-6. 
11.  He Mx, Zhu MH, Zhang YM, Fu qg, Wu LL. Solitary plasmacytoma 
of spine: a clinical, radiologic and pathologic study of 13 cases. 
Zhonghua Bing Li Xue Za Zhi 2009;38:307-11.
12.  Kim PJ, Hicks RJ, Wirth A, Ryan G, Seymour JF, Prince HM, 
Mac Manus MP.Impact of 18F-fluorodeoxyglucose positron 
emission tomography before and after definitive radiation 
therapy in patients with apparently solitary plasmacytoma. Int J 
Radiat Oncol Biol Phys 2009;74:740-6.
13.  Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M. 
Positron emission tomography (PET) for staging of solitary 
plasmacytoma. Cancer Biother Radiopharm 2003;18:841-5. 
14.  Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, 
Samson D. Guidelines on the diagnosis and management of 
solitary plasmacytoma of bone and solitary extramedullary 
plasmacytoma. Clin Oncol 2004;16:405-13.
15.  Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacemi Y, 
Bolla M, Oner FD, Landmann C, Castelain B, Ozsahin Ml. 
Prognostic factors in solitary plasmacytoma of the bone: a 
multicenter Rare Cancer Network study. BMC Cancer 
2006;6:118. 
16.  Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. 
Persistence of myeloma protein for more than one year after 
radiotherapy is an adverse prognostic factor in solitary 
plasmacytoma of bone. Cancer 2002;94:1532-7. 
17.  Kilciksiz S, Celik OK, Pak Y, Demiral AN, Pehlivan M, Orhan O, 
Tokatli F, Agaoglu F, Zincircioglu B, Atasoy BM, Ozseker N, 
Yersal O, Niang U, Haydaroglu A. Clinical and prognostic 
features of plasmacytomas: a multicenter study of Turkish 
Oncology Group-Sarcoma Working Party. Am J Hematol 
2008;83:702-7. 
18.  Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of 
bone and soft tissue. Int J Radiat Oncol Biol Phys 1996;36:329-33. 
19.  Bataille R, Sany J. Solitary myeloma: clinical and prognostic 
features of a review of 114 cases. Cancer 1981;48:845-51.
20.  Aviles A, Huerta-Guzman J, Delgado S, Fernandez A, Diaz-
Maqueo JC. Improved outcome in solitary bone plasmacytomata 
with combined therapy. Hematol Oncol 1996;14:111-7. 
21.  Galieni P, Cavo M, Pulsoni A, Avvisati G, Bigazzi C, Neri S, 
Caliceti U, Benni M, Ronconi S, Lauria F. Clinical outcome of 
extramedullary plasmacytoma. Haematologica 2000;85:47-51. 
22.  Chao MW, Gibbs P, Wirth A, Quong G, Guiney MJ, Liew KH. 
Radiotherapy in the management of solitary extramedullary 
plasmacytoma. Intern Med J 2005;35:211-5. 
23.  Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian 
R. Clinical course of solitary extramedullary plasmacytoma. 
Radiother Oncol 1999;52:245-9. 
24.  Mendenhall CM, Thar TL, Million RR. Solitary plasmacytoma 
of bone and soft tissue. Int J Radiat Oncol Biol Phys 
1980;6:1497-501. 
25.  Susnerwala SS, Shanks JH, Banerjee SS, Scarffe JH, 
Farrington WT, Slevin NJ. Extramedullary plasmacytoma of the 
head and neck region: clinicopathological correlation in 25 
cases. Br J Cancer 1997;75:921-7. 
26.  Jyothirmayi R, Gangadharan VP, Nair MK, Rajan B. Radiotherapy 
in the treatment of solitary plasmacytoma. Br J Radiol 
1997;70:511-6. 
27.  Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary 
plasmacytoma of bone: Mayo Clinic experience. Int J Radiat 
Oncol Biol Phys 1989;16:43-8. 
28.  Chak LY, Cox RS, Bostwick DG, Hoppe RT. Solitary 
plasmacytoma of bone: treatment, progression, and survival. 
J Clin Oncol 1987;5:1811-5.
29.  Bolek TW, Marcus RB, Mendenhall NP. Solitary plasmacytoma of 
bone and soft tissue. Int J Radiat Oncol Biol Phys 1996;36:329-33. 
30.  Holland J, Trenkner DA, Wasserman TH, Fineberg B. 
Plasmacytoma: treatment results and conversion to myeloma. 
Cancer 1992;69:1513-7. 
31.  Mayr NA, Wen BC, Hussey DH, Burns CP, Staples JJ, 
Doornbos JF, Vigliotti AP. The role of radiation therapy in the 
treatment of solitary plasmacytomas. Radiother Oncol 
1990;17:293-303. 
32.  Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN. Localised 
plasmacytomas in Taiwan: comparison between extramedullary 
plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 
1995 71:128-33. 
33.  Galieni P, Cavo M, Avvisati G, Pulsoni A, Falbo R, Bonelli MA, 
Russo D, Petrucci MT, Bucalossi A, Tura S. Solitary 
plasmacytoma of bone and extramedullary plasmacytoma: two 
different entities? Ann Oncol 1995;6:687-91. 
34.  Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, 
Delasalle KB, Libshitz HI, Alexanian R. Prognostic significance of 
magnetic resonance imaging in patients with asymptomatic 
multiple myeloma. J Clin Oncol 1995;13:251-6. 
35.  Mariette X, Zagdanski AM, Guermazi A, Bergot C, Arnould A, 
Frija J, Brouet JC, Fermand JP. Prognostic value of vertebral 
lesions detected by magnetic resonance imaging in patients 
with stage I multiple myeloma. Br J Haematol 1999;104:723-9.
36.  Jackson A, Scarffe JH. Prognostic significance of osteopenia 
and immunoparesis at presentation in patients with solitary 
myeloma of bone. Eur J Cancer 1999;26:363-71.
37.  Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, 
Bida JP, Gertz MA, Therneau TM, Melton LJ 3rd, Dispenzieri A, 
Katzmann JA. Immunoglobulin free light chains and solitary 
plasmacytoma of bone. Blood 2006;108:1979-83.
Koçak et al.
Solitary plasmacytoma Turk J Hematol 2010; 27: 57-61 61